Skip to main content

Table 3 Variables related with SVR at univariate and multivariate analysis (PP).

From: Sustained virological response to peginterferon therapy in patients infected with HCV (genotypes 2 and 3), with or without HIV

 

Univariate analysis

Multivariate analysis

Variables

OR

(IC 95%)

pvalue

OR

(IC 95%)

pvalue

HCV-RNA >500.000 IU/ml

0.4 (0.2-0.7)

0.0019

0.41 (0.23 - 0.75)

0.004

PegIFN alfa-2b vs alfa-2a

0.58 (0.3-1.15)

0.098

0.48 (0.24-0.97)

0.041

Stop RBV

0.25 (0.1-0.5)

0.0001

0.24 (0.1-0.5)

0.0004

PLT <130.000 cell/mm3

0.5 (0.2-1.3)

0.1575

0.83 (0.3-2.2)

0.715

Cirrhosis

0.6 (0.3-1.7)

0.3616

  

Age >45 years

0.7 (0.4-1.2)

0.1868

0.73 (0.4-1.34)

0.31

HIV infection

1.1 (0.5-2.6)

0.8159

1.87 (0.49-7.12)

0.36

RBV reduction

1.7 (0.7-4.6)

0.2287

  

PegIFN reduction

0.9 (0.4-2.2)

0.8685

  

Gender (male vs female)

0.7 (0.3-1.2)

0.1868

0.67 (0.3-1.3)

0.24

HCV genotype 2 vs 3

1 (0.6-1.8)

0.9

  

Variables

SVR no

SVR

yes

p value

OR

(IC 95%)

p value

Weeks of treatment, mean (SD)

27 (14)

25

(12)

0.18

0.98 (0.947-1)

0.39

Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us